Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $11.40 Consensus PT from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $11.40.

A number of analysts have recently weighed in on the stock. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, January 10th. Roth Mkm started coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective for the company. HC Wainwright cut their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in Reviva Pharmaceuticals in the 4th quarter valued at $25,000. Cornerstone Select Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the fourth quarter valued at $32,000. Drive Wealth Management LLC bought a new position in shares of Reviva Pharmaceuticals in the fourth quarter worth about $36,000. XTX Topco Ltd purchased a new position in Reviva Pharmaceuticals in the 4th quarter worth about $45,000. Finally, Tower Research Capital LLC TRC increased its stake in Reviva Pharmaceuticals by 848.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after buying an additional 23,953 shares during the period. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH opened at $1.01 on Thursday. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $4.28. The company’s fifty day moving average is $1.53 and its 200 day moving average is $1.47. The stock has a market capitalization of $33.78 million, a PE ratio of -0.91 and a beta of -0.09.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.